This post was originally published on this site Preliminary data from an ongoing Phase 1 trial suggest that Harpoon Therapeutics’ investigational therapy HPN424 is safe and effectively activates the immune system in metastatic castration resistant prostate cancer (mCRPC) patients. The multicenter, international, open-label study (NCT03577028) is assessing the safety, tolerability and overall stability and distribution of…
This post was originally published on this site Medications currently approved to treat some kinds of breast cancer — generally called CDK4/6 inhibitors — could be re-purposed to treat a rare type of ovarian cancer called small cell carcinoma of the ovary, hypercalcemic type (SCCOHT), a study suggests. The study, “CDK4/6 inhibitors target SMARCA4-determined cyclin D1…
This post was originally published on this site Precigen is preparing to launch a Phase 1 trial to test its investigational therapy PRGN-3005 UltraCAR-T for advanced, platinum-resistant ovarian cancer, after the U.S. Food and Drug Administration (FDA) cleared its investigational new drug (IND) application. The open-label, dose-escalation study will assess the treatment’s safety and maximum tolerated dose.…
This post was originally published on this site A first patient has been given a combination of an investigational therapy, COTI-2, plus standard-of-care chemotherapy in an expanded Phase 1b/2a trial for gynecological and other solid tumors, Cotinga Pharmaceuticals, the potential treatment’s developer, announced. The clinical trial (NCT02433626) was first designed to evaluate the safety and…
This post was originally published on this site A combination of oral Lynparza (olaparib) and weekly chemotherapy can be safely given to heavily treated ovarian cancer patients and shows signs of efficacy, particularly among those with BRCA mutations, a Phase 1/2 trial shows. The findings suggest that weekly chemotherapy might be more suitable for these patients…
This post was originally published on this site Losartan, a medicine used for treating high blood pressure, might improve ovarian cancer treatment by making it easier for chemotherapy drugs to get to tumor cells, a study found. Patients with advanced ovarian cancer receiving losartan or other similar angiotensin signaling inhibitors lived a median 30 months longer on standard…
This post was originally published on this site The Multiple Myeloma Research Foundation (MMRF) is reworking its executive team, with a focus on improving multiple myeloma patient outcomes and advancing its precision medicine program. Steve Labkoff, MD, becomes the organization’s first chief data officer, while Michael Andreini is the new chief operating officer. Meanwhile, Daniel Auclair,…
This post was originally published on this site The development and commercialization of TNB-383B — an anti-BCMA antibody for the potential treatment of multiple myeloma — is being advanced as part of a new collaboration between AbbVie, Teneobio, and its affiliate TeneoOne. Under terms of the agreement, TeneoOne will continue to develop TNB-383B through Phase 1 clinical…
This post was originally published on this site More than half of all deaths related to asbestos exposure is caused by malignant mesothelioma, a new study has shown. The study, “Risk Factors of Mortality from All Asbestos-Related Diseases: A Competing Risk Analysis,” was published in the journal Canadian Respiratory Journal. Asbestos is known to be responsible for several…
This post was originally published on this site A case study diagnosing sarcoidosis upon autopsy in a patient with acute respiratory distress syndrome (ARDS) of unknown cause highlights the importance of physicians taking into account this uncommon disease association for quicker diagnosis and treatment. The study, “Sarcoidosis Presenting as Acute Respiratory Distress Syndrome,” was published in…
